The company markets this as the same price at every dose level, with no hidden fees
Abstract Glucagon-like peptide 1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, represent highly effective treatment options for people with type 2 diabetes and obesity, enabling effective control of glucose and weight loss, while reducing cardiovascular and renal morbidity and mortality
As the dosage reaches the therapeutic level, you are more likely to notice a significant reduction in hunger
Lancet 404 , 773786 (2024)
Additional symptoms that may occur include headache, fatigue, and general malaise
Obesity is a chronic condition requiring ongoing management to maintain weight loss